DURECT Corporation (NASDAQ:DRRX) biopharmaceutical researcher, is reporting third quarter earnings results on Monday 2nd November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.04 per share.
For the full year, analysts predict revenues of $ 36.22 million, while looking forward to loss of $ 0.06 per share.
Previous Quarter Performance
DURECT Corporation reported income for the second quarter of $ 0.07 per share, from the revenue of $ 25.84 million. The quarterly revenues improved 542.79 percent compared with the same quarter last year. According to street consensus, revenue of $ 11.48 million was expected for the second quarter The top line results outshined analysts by $ 14.36 million or 125.09 percent.
Stock Performance
On Friday, shares of DURECT Corporation has traded high as $ 1.85 and has cracked $ 1.75 on the downward trend, reaching $ 1.81 with volume of 661.10 thousand shares.
According to the previous trading day, closing price of $ 1.81, representing a 85.26 % increase from the 52 week low of $ 0.95 and a 55.44 % decrease over the 52 week high of $ 3.95.
The company has a market capital of $ 362.04 million and is part of the Healthcare sector and Drug Manufacturers – Specialty & Generic industry.
Recent Analyst recommendations
- On 12th October 2020, initiated by Roth Capital at Buy rating, with $ 7.00 target price.
Conference Call
DURECT Corporation will be hosting a conference call at 4:30 PM eastern time on 2nd November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.durect.com
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase I and II development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival.
